

MMP-9 Inhibitor I

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 206549-55-5 |
| Formula: | C27H33N3O5S |
| Molecular Weight: | 511.63 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |

Biological Description

| | |
|----------------------------|--|
| Description | MMP-9 Inhibitor I is an inhibitor of matrix metalloproteinase-9 (MMP-9) that is selective over MMP-1 and MMP-13 (IC ₅₀ s = 5, 1,050, and 113 nM, respectively). MMP-9 Inhibitor I also decreases activity of TNF- α converting enzyme (TACE) in a dose-dependent manner (IC ₅₀ = 0.54 μ M). MMP-9 Inhibitor I decreases TNF- α secretion stimulated by LPS in BV-2 microglial cells at concentrations of 50 and 100 μ M. MMP-9 Inhibitor I is therefore used in neuroinflammatory and extracellular matrix regulation research to investigate metalloproteinase selectivity, cytokine shedding pathways, and microglial activation responses in cellular inflammation models. |
| Targets(IC ₅₀) | MMP |
| In vitro | <p>Methods: Cells and recombinant proteins were treated with MMP-9 Inhibitor I at different concentrations. Its effects on inflammatory factor secretion as well as the activities of TACE and MMP-9 were detected.</p> <p>Results:</p> <ol style="list-style-type: none"> 1.Treatment with 1-100 μM MMP-9 Inhibitor I for 1 hour inhibited LPS-induced TNF-α secretion in mouse BV2 microglia in a dose-dependent manner. 2.MMP-9 Inhibitor I at 0.1-1 μM suppressed the activity of recombinant human TACE, with an IC₅₀ value of 0.54 μM. 3.After 1-hour treatment with 80 nM MMP-9 Inhibitor I, the cleavage of pro-TNF-α peptide (residues 71-82) by recombinant MMP-9 was specifically blocked [1]. |

Solubility Information

| | |
|------------|--|
| Solubility | <p>DMF: 20 mg/mL (39.09 mM),Sonication is recommended.</p> <p>DMSO: 80 mg/mL (156.36 mM),Sonication is recommended.</p> <p>Ethanol: 33 mg/mL (64.5 mM),Sonication is recommended.</p> <p>Ethanol:PBS (pH 7.2) (1:8): 0.11 mg/mL (0.21 mM),Sonication is recommended.</p> <p>(< 1 mg/ml refers to the product slightly soluble or insoluble)</p> |
|------------|--|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|------------|
| 1 mM | 1.9545 mL | 9.7727 mL | 19.5454 mL |
| 5 mM | 0.3909 mL | 1.9545 mL | 3.9091 mL |
| 10 mM | 0.1955 mL | 0.9773 mL | 1.9545 mL |
| 50 mM | 0.0391 mL | 0.1955 mL | 0.3909 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Lee EJ, et al. Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF- α Release from Activated Microglia and TNF- α Converting Enzyme Activity. *Biomol Ther (Seoul)*. 2014;22(5):414-419.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481